Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(5.29) per share which missed the analyst consensus estimate of $(4.35) by 21.58 percent. This is a 40.56 percent increase over losses of $(8.90) per share from the same period last year. The company reported quarterly sales of $11.647 million which beat the analyst consensus estimate of $8.341 million by 39.64 percent. This is a 21.35 percent decrease over sales of $14.809 million the same period last year.